Registry, Dec 31, 2029
Dosing n/r
B7-H4-directed ADC · AstraZeneca
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
ACC pipeline
Programs by company or class, across phase, filing, approval, and a stop.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
21 of 23 programs on this matrix
| Phase 2 | Phase 3 | Filed | Approved | Discontinued | |
|---|---|---|---|---|---|
| AstraZeneca1 program | Registry, Dec 31, 2029 Dosing n/r B7-H4-directed ADC · AstraZeneca | ||||
| Ayala Pharmaceuticals1 program | Phase 2 Dosing n/r gamma secretase inhibitor · Ayala Pharmaceuticals | ||||
| Cellestia Biotech1 program | Registry, Jun 2027 oral (not re-verified) pan-NOTCH transcription inhibitor · Cellestia Biotech | ||||
| Dana-Farber Cancer Institute1 program | Registry, Jul 2027 Dosing n/r PD-1 x VEGF bispecific · Dana-Farber Cancer Institute | ||||
| Eisai (investigator studies)1 program | Registry, Dec 2026 once daily, oral VEGFR multi-kinase TKI · Eisai (investigator studies) | ||||
| Elevar Therapeutics1 program | Trials stopped once daily, oral Registry records are terminated or withdrawn. VEGFR2 TKI · Elevar Therapeutics | ||||
| Exelixis1 program | Registry, Apr 2029 Dosing n/r VEGFR/MET/TAM TKI · Exelixis | ||||
| Eye and ENT Hospital of Fudan University1 program | Registry, Jun 2028 Dosing n/r multi-kinase TKI with chemotherapy · Eye and ENT Hospital of Fudan University | ||||
| HitGen1 program | Registry, Dec 31, 2028 Dosing n/r HDAC inhibitor · HitGen | ||||
| Memorial Sloan Kettering1 program | Registry, Mar 2027 Dosing n/r Nectin-4-directed ADC · Memorial Sloan Kettering | ||||
| Memorial Sloan Kettering (investigator)1 program | Phase 2 oral multi-kinase TKI · Memorial Sloan Kettering (investigator) | ||||
| National Cancer Centre Singapore1 program | Registry, Oct 31, 2028 Dosing n/r TROP2-directed ADC · National Cancer Centre Singapore | ||||
| National Cancer Institute1 program | Registry, Oct 2036 Dosing n/r CXCR1/2 inhibitor · National Cancer Institute | ||||
| Pfizer1 program | Phase 2 twice daily, oral VEGFR TKI · Pfizer | ||||
| Radboud UMC; Johns Hopkins (investigators)1 program | Phase 2 intravenous PSMA radioligand · Radboud UMC; Johns Hopkins (investigators) | ||||
| Remix Therapeutics (merging with Passage Bio)1 program | ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026 once daily, oral, once daily MYB mRNA degrader · Remix Therapeutics (merging with Passage Bio) | ||||
| Servier (registry sponsor Day One Biopharmaceuticals)1 program | Registry, Feb 2027 every 4 weeks, intravenous B7-H4-directed ADC · Servier (registry sponsor Day One Biopharmaceuticals) | ||||
| Shanghai Ninth People's Hospital1 program | Phase 2 Dosing n/r VEGFR2 TKI · Shanghai Ninth People's Hospital | ||||
| Trisha Wise-Draper (investigator)1 program | Phase 2 intravenous EGFR x MET bispecific antibody · Trisha Wise-Draper (investigator) | ||||
| University of Michigan1 program | Phase 1/2 Dosing n/r MDM2 inhibitor · University of Michigan | ||||
| VM Oncology1 program | Registry, Dec 2027 Dosing n/r TrkA inhibitor · VM Oncology |